DEF: OrthoPediatrics Corp. Announces 2025 Annual Meeting of Stockholders

OrthoPediatrics Corp. will hold its 2025 annual meeting of stockholders on May 23, 2025, to elect directors, approve executive compensation, and ratify the appointment of Deloitte & Touche LLP as its independent auditor.

Summary

• OrthoPediatrics Corp. is holding its annual meeting of stockholders on May 23, 2025, at The St. Louis Club in St.
• Louis, Missouri.
• The meeting will cover the election of four directors to serve until the 2028 annual meeting, an advisory vote on executive compensation, and an advisory vote on the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The record date for determining stockholders eligible to vote is March 28, 2025.
• The company will begin sending a Notice of Internet Availability of Proxy Materials on or about April 11, 2025, allowing stockholders to access proxy materials online and vote electronically.
• As of the record date, 24,831,427 common shares were issued and outstanding, held by approximately 681 registered stockholders of record.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. It provides necessary information for stockholders to make informed decisions, reflecting a professional and compliant approach.

Positives

• The company is providing stockholders with convenient online access to proxy materials, reducing costs and conserving resources.
• The Board is actively engaged in risk oversight, with committees dedicated to managing specific risk areas.
• The company has a clawback policy in place to recover erroneously awarded compensation from executive officers.
• The company maintains a code of ethics and business conduct policy for directors, officers, and employees.
• The company encourages diversity on the Board and has added diverse directors in recent years.
• The company has stock ownership guidelines for directors to align their interests with those of stockholders.

Risks

• The advisory votes on executive compensation and the appointment of the independent auditor are non-binding, meaning the Board is not obligated to follow the stockholders' recommendations.
• The company faces cybersecurity risks, requiring ongoing monitoring and updates to preventive measures.
• Related party transactions, such as those with Structure Medical and Tawani Enterprises Inc., could present potential conflicts of interest.

Future Outlook

The company expects to continue to increase its disclosures and communicate its social impact efforts in future SEC filings.

Management Comments

• Thank you for your continued support of OrthoPediatrics Corp.
• We look forward to seeing you at the annual meeting.

Industry Context

This announcement is a routine part of corporate governance for publicly traded companies, ensuring stockholders have the opportunity to participate in key decisions.

Comparison to Industry Standards

• The proxy statement adheres to SEC regulations, similar to those of comparable companies such as Stryker, Zimmer Biomet, and Medtronic.
• The company's executive compensation practices are in line with industry standards, as determined by the Compensation Committee's review of peer group data.
• The company's corporate governance practices, including the presence of independent directors and key committees, align with Nasdaq listing requirements and best practices.

Related Party Transactions

• The company has supply relationships with Structure Medical, LLC, owned by Squadron Capital LLC, resulting in payments of $1.0 million in 2024 and $1.1 million in 2023.
• The company has an exclusive perpetual license arrangement with Vilex, LLC, a wholly-owned subsidiary of Squadron, with sales and payments related to inventory purchases and related services to Vilex, LLC, were $0.2 million and $0.1 million, respectively in 2024.
• The company has a mortgage note payable to Tawani Enterprises Inc., owned by a member of Squadron's Managing Committee, with a balance of $0.6 million as of December 31, 2024.

Stakeholder Impact

• Stockholders have the opportunity to vote on key decisions, influencing the direction and governance of the company.
• Executive compensation decisions impact the motivation and retention of key management personnel.
• The appointment of the independent auditor ensures the integrity of the company's financial reporting.
• The company's social impact initiatives aim to improve the lives of children with orthopedic conditions, benefiting patients and their families.

Next Steps

• Stockholders are urged to vote on the proposals outlined in the proxy statement.
• The company will hold its annual meeting on May 23, 2025.
• The Board will consider the results of the advisory votes on executive compensation and the appointment of the independent auditor.

Key Dates

Keywords

annual meeting, proxy statement, directors, executive compensation, Deloitte & Touche LLP, stockholders, OrthoPediatrics